


Systemic Organ Function and Implant Healing: Kidney, Liver, Gut and Bone Metabolism

How mineral regulation, organ disease, nutrition and medical treatment shape individualized implant planning



Core message: bone healing reflects local surgical conditions and systemic regulation. Kidney, liver and intestinal disease can alter mineral balance, nutrition, immunity, medication handling or procedural safety, but the diagnosis alone does not predict implant failure.

Educational material for dental students, postgraduate trainees and academic teachers

Bone as a systemically regulated tissue

Bone continuously integrates endocrine, renal, hepatic, intestinal, vascular and immune signals. The skeleton stores minerals and adapts to load, while osteoblasts, osteoclasts and osteocytes respond to calcium-phosphate balance, parathyroid hormone, vitamin D, inflammatory mediators and nutritional supply.

System	Principal contribution	Potential relevance to implant healing
Kidneys	Phosphate excretion, activation of vitamin D, acid-base balance and endocrine signalling.	CKD can disturb turnover, mineralization and bone volume through CKD-MBD.
Liver	Protein synthesis, nutrient metabolism, bile production, inflammatory regulation and vitamin D 25-hydroxylation.	Advanced disease can affect nutrition, haemostasis, immunity and medication handling.
Intestine	Absorption of minerals, vitamins, protein and medicines; immune and microbiome interactions.	Inflammation, resection or malabsorption can create deficiencies and treatment complexity.
Endocrine and adipose tissues	Glucose, insulin, adipokines and sex-hormone regulation.	Metabolic clustering can modify inflammation and regeneration.
Local jaw environment	Blood supply, surgical trauma, stability, biofilm, tissue dimensions and loading.	Local factors remain necessary for interpreting every complication.

Normal anatomy does not prove normal physiology

CBCT provides information about bone dimensions and radiographic architecture. It cannot directly measure turnover, mineralization, collagen quality, marrow composition or cellular healing capacity. Conversely, systemic disease does not prove that jawbone is unsuitable for treatment.

Integrated assessment: combine local examination and imaging with the current medical course, treatment, functional status and targeted laboratory information.

Metabolic clustering and shared pathways

Diabetes, obesity, dyslipidaemia and metabolic dysfunction-associated steatotic liver disease often coexist. Chronic low-grade inflammation, oxidative stress and insulin resistance provide a plausible shared background, but they do not form one uniform implant-risk category.

Pathway	Possible influence on healing	Reason for caution
Hyperglycaemia and advanced glycation	Altered collagen, immune response, angiogenesis and bone-cell function.	Current control and complications matter more than the diagnosis alone.
Adipose dysfunction	Adipokine imbalance and inflammatory signalling may alter host response.	BMI does not directly measure visceral adiposity or metabolic health.
Dyslipidaemia	Modified lipids may affect oxidative and bone-remodelling pathways.	Human implant evidence remains limited and confounded.
MASLD	Signals systemic metabolic dysfunction and may progress to fibrosis or cirrhosis.	Simple steatosis and advanced liver disease have very different procedural implications.
Reduced activity and nutrition	Can affect muscle, bone loading, protein supply and self-care.	These factors require direct assessment rather than assumption.

Risk accumulates without becoming deterministic

Several moderate concerns may justify staging, medical coordination or closer follow-up. None creates a guarantee of failure. The same patient may also have excellent plaque control, favourable anatomy and stable medical management.

Avoid repeating unvalidated panels

Metabolic screening should answer a defined question. Ordering glucose, lipids, inflammatory indices, vitamin D, PTH and organ tests for every implant candidate risks incidental findings and false certainty.

Clinical question first: select a test only when its result can change timing, technique, prescribing, referral or follow-up.

Chronic kidney disease and CKD-MBD

Chronic kidney disease-mineral and bone disorder is a systemic disorder of mineral and skeletal metabolism caused by CKD. It can include biochemical abnormalities, altered bone turnover or mineralization, fractures and vascular or soft-tissue calcification. Bone disease can range from high-turnover secondary hyperparathyroidism to low-turnover adynamic bone.

Component	Change in CKD	Clinical meaning
Phosphate and FGF-23	Phosphate retention and increased FGF-23 can occur as kidney function declines.	Contributes to reduced calcitriol and altered mineral regulation.
Vitamin D metabolism	Renal activation of vitamin D becomes impaired.	May reduce calcium absorption and contribute to secondary hyperparathyroidism.
Parathyroid hormone	PTH may rise in response to mineral imbalance.	Persistent elevation may indicate high turnover, but one value needs trend and CKD-stage context.
Bone turnover	Turnover may be high, low or mixed.	Both excessive resorption and suppressed remodelling can affect healing.
Anaemia and uraemia	Advanced CKD can affect oxygen delivery, immunity, bleeding and drug clearance.	Procedural implications extend beyond bone metabolism.

Interpret serial values together

KDIGO recommends decisions based on trends and the combined interpretation of calcium, phosphate and PTH rather than one isolated value. Alkaline phosphatase and vitamin D status may add context. The nephrology team determines monitoring frequency and treatment according to CKD stage and current therapy.

Implant evidence is limited

Published clinical reports show that implants can integrate in selected patients with CKD, including some receiving dialysis. Small samples and heterogeneous disease severity prevent a universal survival estimate. Stable medical management and careful selection remain essential.

CKD is not one bone phenotype: ask about stage, dialysis, transplantation, CKD-MBD, anaemia, current laboratory trends and medication.

PTH, vitamin D and sclerostin

Mineral regulation involves connected pathways. PTH responds to calcium-phosphate balance, vitamin D supports intestinal calcium absorption and bone mineral physiology, and sclerostin limits Wnt/beta-catenin signalling in osteoblast-lineage cells.

Marker or pathway	Useful interpretation	Common overreach
PTH	Interpret with CKD stage, calcium, phosphate, vitamin D status and serial change.	Calling any elevation direct proof of jawbone resorption.
25-hydroxyvitamin D	Reflects vitamin D status and may be measured for medical indications or deficiency risk.	Using one universal dental target or promising implant benefit from supplementation.
Calcium and phosphate	Part of mineral balance and CKD-MBD monitoring.	Interpreting values without albumin, kidney function or treatment context.
Alkaline phosphatase	Can contribute information about turnover; bone-specific assays may be used in selected care.	Assuming total enzyme activity comes only from bone.
Sclerostin	Mechanistically links osteocytes with Wnt inhibition and bone formation.	Using it as a routine dental biomarker; CKD interpretation remains complex.

Secondary hyperparathyroidism

Secondary hyperparathyroidism can develop in CKD, vitamin D deficiency or other causes of disturbed mineral balance. Persistent disease can increase bone turnover, but treatment or advanced CKD may also produce low-turnover states. The dental team should not infer turnover from PTH alone.

Targeted testing

PTH, calcium, phosphate, magnesium, alkaline phosphatase and 25-hydroxyvitamin D should not form an automatic implant panel. They are appropriate when the history, CKD stage, malabsorption, fracture risk or medical team provides a clear indication.

Single-marker caution: mineral and bone disorders require patterns, trends and clinical context. Sclerostin currently has no routine role in implant qualification.

Liver disease and implant planning

The clinical implications of liver disease depend on aetiology and severity. MASLD often reflects insulin resistance and cardiometabolic clustering. Advanced fibrosis, cirrhosis or decompensation can add nutritional, haemostatic, immune and medication-related concerns that simple steatosis does not imply.

Liver context	Potential relevance	Assessment boundary
MASLD without advanced disease	Signals metabolic dysfunction and cardiovascular risk.	Does not by itself prove impaired coagulation or surgical healing.
Advanced fibrosis or cirrhosis	May involve thrombocytopenia, portal hypertension, altered drug handling, malnutrition and infection risk.	Routine coagulation tests incompletely represent balanced haemostasis in cirrhosis.
Decompensated disease	Ascites, encephalopathy, variceal bleeding or jaundice indicate major instability.	Elective invasive care requires specialist coordination and appropriate setting.
Alcohol-related disease	May combine hepatic injury, nutritional deficiency and behavioural exposure.	Use neutral history taking and assess current stability.
Transplantation	Immunosuppression, organ function and infection prevention affect timing and care.	Coordinate with the transplant team; do not alter immunosuppression.

Coagulation requires diagnosis-specific interpretation

Liver disease should not be treated as synonymous with bleeding. Platelet count, INR and clinical history may be relevant in advanced disease, but their interpretation and any correction plan belong within coordinated medical care. Dental prescribing must account for hepatic metabolism and interactions.

Vitamin D and nutrition

The liver participates in vitamin D 25-hydroxylation and protein synthesis. Advanced disease can coexist with sarcopenia, low protein intake and micronutrient deficiency. These findings require medical and nutritional assessment rather than empiric supplementation.

Differentiate phenotype: metabolic steatosis, advanced fibrosis, cirrhosis and transplant status carry different procedural implications.

Inflammatory bowel disease and malabsorption

Crohn disease and ulcerative colitis differ in distribution, complications and treatment. Implant evidence is sparse, mostly observational and concentrated in Crohn disease. Active inflammation, intestinal resection, corticosteroid exposure, biologic therapy, anaemia and nutritional status may matter more than the label alone.

Clinical domain	Potential concern	Action
Disease activity	Active inflammation can affect nutrition, fatigue and infection risk.	Clarify current control, recent flare and treating team.
Malabsorption or resection	Iron, vitamin B12, folate, vitamin D, calcium, magnesium and protein deficits may occur.	Use targeted tests or dietetic review when indicated by history.
Corticosteroids	Long-term exposure can affect bone, glucose, infection response and adrenal physiology.	Record dose and duration; coordinate major surgery when risk is relevant.
Biologic or other immunomodulatory therapy	Infection risk and timing considerations differ by drug and disease activity.	Do not independently interrupt treatment; use focused specialist advice.
Oral and periodontal disease	IBD can coexist with oral inflammation and periodontitis.	Stabilize local disease and establish a maintainable prosthetic design.

The microbiome is a research framework

Gut and oral microbial communities interact with immunity and metabolism, but no microbiome test currently determines implant eligibility. Probiotics, restrictive diets or microbiome-directed interventions should not replace established medical and dental care.

Human evidence remains limited

A 2022 systematic analysis found only six relevant clinical studies, all involving Crohn disease, with substantial associated risk factors. This evidence supports collaboration and monitoring rather than a categorical contraindication.

IBD care focuses on current status: disease activity, nutrition, medication and local infection control provide more actionable information than the diagnosis alone.

Medication and comorbidity review

Organ disease often brings polypharmacy. Medication can modify immune response, bone turnover, bleeding, renal or hepatic clearance and appointment tolerance. The aim is to preserve necessary systemic treatment while adapting dental care safely.

Exposure	Possible relevance	Safe principle
Corticosteroids	Bone loss, hyperglycaemia, infection response and adrenal suppression with prolonged or substantial exposure.	Do not change therapy independently; assess current dose and medical plan.
Immunosuppressants and biologics	Drug-specific infection and healing considerations.	Coordinate only when the procedure and disease status justify it.
Antiresorptives	MRONJ risk depends on agent, indication, dose, route and duration.	Use a separate medication-specific risk assessment.
SSRIs	Observational studies report possible associations with bone outcomes and implant failure.	Confounding by depression and comorbidity limits causal inference; not an automatic contraindication.
Renally or hepatically cleared medicines	Accumulation or toxicity can occur when organ function declines.	Check current prescribing guidance and coordinate dose decisions with medical care.

Depression and functional context

Depression can influence activity, nutrition, smoking, sleep and adherence. Ask about self-care capacity and support directly rather than attributing risk to medication or diagnosis alone.

Medication interruption can create greater harm

Stopping immunosuppression, anticoagulation, corticosteroids or other long-term treatment can destabilize serious disease. A dental procedure must be described clearly before a responsible clinician considers any modification.

Medication principle: adapt the dental plan around necessary systemic treatment whenever possible. Any change requires a documented, individualized medical decision.

A targeted pre-operative pathway

Step	Clinical action	Decision supported
1. Define the condition	Record organ diagnosis, stage, current activity, complications and treating team.	Distinguishes stable chronic disease from active instability.
2. Review treatment	Record medicines, dialysis or transplant schedule, recent changes and adverse effects.	Guides timing, prescribing and coordination.
3. Establish local readiness	Assess periodontitis, plaque, infection, bone anatomy, tissue conditions and prosthetic access.	Identifies direct and modifiable oral risk.
4. Use existing data	Review recent medically indicated laboratory results before ordering additional tests.	Reduces duplication and preserves correct interpretation.
5. Request targeted information	Ask a focused question about stability, haemostasis, infection, drug dosing or mineral disorder.	Links consultation to an actionable decision.
6. Adapt treatment and follow-up	Consider staging, reduced invasiveness, healing review and individualized maintenance.	Matches procedural burden to combined risk.

Possible tests depend on the question

Examples include HbA1c for diabetes control, kidney function and CKD-MBD markers in established CKD, blood count in anaemia or immunosuppression, and liver or haemostatic studies in advanced hepatic disease. CRP and CBC-derived inflammatory indices are nonspecific and should not function as universal implant screens.

When elective care should pause

Acute organ decompensation, uncontrolled systemic infection, major unexplained laboratory disturbance or an unstable treatment course warrants medical assessment before elective implant surgery. Urgent dental infection still requires timely management in an appropriate setting.

Proportionate preparation: combine medical stability, local disease control and a procedure of suitable complexity. More testing does not automatically produce safer care.

Clinical synthesis and selected references

Clinical synthesis

- Recognize that kidney, liver and intestinal disease can affect bone through different pathways and at different levels of severity.
- Do not infer biological bone quality from CBCT appearance alone.
- Interpret CKD-MBD through calcium, phosphate, PTH and other data as trends within CKD-stage context.
- Distinguish MASLD from advanced fibrosis, cirrhosis and decompensated liver disease.
- Assess IBD through activity, malabsorption, medication and nutritional status rather than diagnosis alone.
- Avoid universal metabolic laboratory panels and unvalidated biomarker cutoffs.
- Do not independently interrupt immunosuppression, corticosteroids or other essential treatment.
- Use focused medical coordination when the answer changes timing, prescribing, procedural complexity or follow-up.

Selected references

1. KDIGO. 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of CKD-MBD. *Kidney International Supplements*. 2017;7:1-59.
2. Ketteler M, et al. Chronic kidney disease-mineral and bone disorder: conclusions from a KDIGO Controversies Conference. 2025.
3. Kanjevac T, et al. Impact of chronic kidney disease-mineral and bone disorder on jaw and alveolar bone metabolism. 2018. PMID: 29459907.
4. Alla I, et al. Implant survival in patients with chronic kidney disease: a systematic review and case reports. 2023. PMID: 36767768.
5. EASL-EASD-EASO. Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease. *Journal of Hepatology*. 2024.
6. Voina-Tonea A, et al. Dental implant failure in patients with inflammatory bowel disease: a systematic analysis of human clinical studies. 2022. PMID: 35334519.
7. Duttenhoefer F, et al. Dental implants in immunocompromised patients: a systematic review and meta-analysis. 2019. PMID: 31776815.
8. D'Ambrosio F, et al. Do systemic diseases and medications influence dental implant osseointegration and outcomes? 2023.
9. Werny JG, et al. Does vitamin D have an effect on osseointegration of dental implants? A systematic review. 2022. PMID: 35403929.
10. Guobis Z, et al. General diseases influence on peri-implantitis development: a systematic review. 2016. PMID: 27833730.

Educational use and limitations

This material supports risk assessment and interdisciplinary communication. It does not replace nephrology, hepatology, gastroenterology or individualized medical management.

Funding statement

This work was co-funded by the European Union under grant agreement No. 2024-1-PL01-KA220-HED-000251208. Views and opinions expressed are those of the author(s) only and do not necessarily reflect those of the European Union or the Foundation for the Development of the Education System (FRSE). Neither the European Union nor FRSE can be held responsible for them.